(Source: AbbVie Inc) Data from 25 accepted abstracts include results from: -- AbbVie's investigational treatment in liver transplant recipients with recurrent genotype 1 (GT1) chronic hepatitis C virus (HCV) infection and in GT1 HCV patients with human immunodeficiency virus type 1 co-infection -- Abstracts evaluating AbbVie's investigational treatment combining two direct-acting antivirals with or without ribavirin (RBV) in patients with genotype 4 chronic HCV infection -- Trials of other pipeline compounds ABT-493 and ABT-530 in GT1 chronic HCV infection Oct 1, 2014 NORTH CHICAGO, Ill. , Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1...
↧